Zhang, Y., Nie, M., Cao, Y., Li, Z., Huang, H., Li, G., Sun, X., Liu, P., Gao, Y., Fang, X., Bai, B., Cai, J., Li, L., Liu, Y., Peng, S., Huang, H., Xia, Y., Cai, Q. (2026). Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial. Nature Communications. https://doi.org/10.1038/s41467-026-71241-1